Investors’ enthusiasm for weight loss drugs has turbocharged the share prices of Novo Nordisk and Eli Lilly, leaving many other big pharmaceutical companies looking like also-rans.
Few things are as alluring to investors as a growing dividend. Companies that are able to raise their payouts continually have widespread appeal, and not just to investors who focus on income.